Drugs and Pharmaceuticals
Free News Articles Category: Drugs and Pharmaceuticals Industry News Articles
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome
CARY, N.C. — Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company’s lead drug RSC-57, for the treatment of patients with Kabuki Syndrome….
Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson
AUSTIN, Texas — Kalyagen is pleased to announce the launch of its “Stem the Tide of Time” social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM)….
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients
AUSTIN, Texas — Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure,” to evaluate the use of stem cell therapies in patients suffering from heart failure….
EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group
SAN FRANCISCO, Calif. — EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation’s largest independent pharmacy benefit consulting firm into EPIC’s Employee Benefits Consulting practice….
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program
AUSTIN, Texas — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform….
Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology
CHRISTIANSBURG, Va. — Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology….
NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor
CAMBRIDGE, Mass. — NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company’s Medical Advisor of Infectious Disease….
US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend
DECATUR, Ga. — US Pharmaceutical Corporation, the probiotic and nutritional supplement company, launches Hylafem pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women’s vaginal health issues….
Thar Process Expands into India to Focus on Pharmaceutical Purification Market
PITTSBURGH, Pa. — Thar Process, Inc – an American manufacturer of high-tech supercritical CO2 extraction and purification equipment – is proud to announce the signing of a new exclusive distribution deal with YMC India (a subsidiary of YMC Co. Ltd., JAPAN)….
A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients
PARK CITY, Utah — Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients’ lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties….